RE:BetaI think the company is doing great. Even after buying back shares back they have more cash. They survived Covid, and grew the company. The financial show everything. They hired 54 people so far this year.
The stock really should of moved up more because of earnings. April was a great month to start the second quarter. The guidance s great.
The market is just weak, and people are afraid to buy. I'm okay with that, because the company is dViemed Healthcare, Inc. Fiscal Year Ends December Mar-20A Jun-20A Sep-20A Dec-20A Mar-21A Jun-21A Sep-21A Dec-21A Mar-22A Jun-22E Sep-22E Dec-22E Income Statement Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Dollars in Millions, Ex per unit measures Core Business 80.3 22.8 23.1 24.9 26.1 96.9 25.5 26.3 27.8 28.9 108.5 30.2 32.1 33.4 34.7 130.4 156.5 COVID-19 Related - 1.0 19.7 8.6 5.1 34.4 3.0 1.1 1.5 3.0 8.6 2.1 0.2 1.0 1.0 4.3 4.0 Total Revenue 80.3 23.8 42.9 33.4 31.2 131.3 28.4 27.4 29.3 32.0 117.1 32.3 32.3 34.4 35.7 134.7 160.5 Total Cost of Revenue 24.3 8.3 16.9 14.0 12.0 51.2 10.7 9.8 10.9 12.3 43.7 12.5 11.8 12.6 13.1 50.1 58.8 Gross Profit 56.0 15.6 25.9 19.5 19.2 80.1 17.7 17.6 18.4 19.7 73.4 19.7 20.5 21.8 22.6 84.6 101.7 Operating Cost and Expenses SG&A 41.4 10.6 16.4 13.6 12.3 52.8 14.5 12.9 13.3 14.2 54.9 15.8 15.5 16.5 17.2 64.9 75.9 Research And Development 0.8 0.2 0.3 0.2 0.4 1.1 0.3 0.6 0.6 0.6 2.1 0.6 0.6 0.6 0.6 2.4 2.8 Stock-based Compensation 3.9 1.2 1.2 1.2 1.3 4.9 1.3 1.2 1.3 1.3 5.2 1.3 1.4 1.5 1.5 5.7 6.6 Depreciation 0.7 0.2 0.2 0.2 0.2 0.8 0.2 0.2 0.2 0.2 0.9 0.2 0.3 0.3 0.3 1.1 1.6 Loss (gain) on Disposal of Prop & Equip 0.4 (1.2) (1.5) 0.2 0.1 (2.3) 0.1 0.1 0.1 0.1 0.4 0.2 0.2 0.2 0.6 0.8 Loss on Warrant conversion Liability / Other 0.1 - - - - (0.0) (0.0) (0.0) - (0.1) - - - - - - Other Expense - - (3.6) (0.0) (0.4) (4.0) - - - (1.5) (1.5) (0.5) - - - (0.5) - Total Operating Expenses 47.3 10.9 13.1 15.4 13.9 53.3 16.4 15.0 15.5 15.0 61.8 17.5 18.0 19.1 19.8 74.4 87.7 Operating Income (Loss) 8.7 4.6 12.9 4.0 5.3 26.8 1.3 2.7 2.9 4.7 11.6 2.2 2.5 2.7 2.9 10.3 14.0 Interest Expense / Loss on Warrant Conversion / Equity Method Investments (0.0) 0.2 0.1 0.1 0.0 0.4 (0.1) (0.1) (0.3) (0.4) (0.9) (0.3) (0.3) (0.3) (0.3) (1.0) (1.0) Net Income (Loss) Before Income Taxes 8.8 4.4 12.8 3.9 5.2 26.4 1.5 2.8 3.2 5.1 12.5 2.5 2.7 2.9 3.1 11.3 15.1 Income Taxes 0.3 0.2 (6.6) 1.1 0.2 (5.2) (0.2) 1.2 1.4 1.0 3.4 0.7 0.5 0.5 0.5 2.2 2.6 Net Income (Loss) 8.5 4.2 19.4 2.8 5.1 31.5 1.7 1.6 1.8 4.1 9.1 1.8 2.3 2.4 2.6 9.1 12.5 Net income (Loss) / share - Basic & Diluted $0.21 $0.11 $0.48 $0.07 $0.12 $0.77 $0.04 $0.04 $0.04 $0.10 $0.22 $0.04 $0.06 $0.06 $0.06 $0.22 $0.30 Adj. EPS (Excludes Tax, CARES Benefit Q2'20) $0.22 $0.11 $0.23 $0.10 $0.12 $0.55 $0.04 $0.07 $0.08 $0.09 $0.27 $0.05 $0.07 $0.07 $0.08 $0.27 $0.36 Weighted Avg. Shares Out. Basic & Diluted (M) 39.7 40.1 40.8 41.2 41.0 40.8 40.7 41.0 40.7 40.5 40.7 40.4 40.6 40.8 41.0 40.7 41.5 GAAP Net Income 8.5 4.2 19.4 2.8 5.1 31.5 1.7 1.6 1.8 4.1 9.1 1.8 2.3 2.4 2.6 9.1 12.5 Depreciation and Amortization 6.4 2.1 2.2 2.4 2.8 9.6 2.6 2.7 2.9 3.1 11.3 3.4 3.3 3.6 4.0 14.3 16.4 Interest Expense 0.3 0.2 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.3 Loss on Financial Derivative (0.4) - - - - - - Stock-based compensation 3.9 1.2 1.2 1.2 1.3 4.9 1.3 1.2 1.3 1.3 5.2 1.3 1.4 1.5 1.5 5.7 6.6 Income tax expense (recovery) 0.3 0.2 (6.6) 1.1 0.2 (5.2) (0.2) 1.2 1.4 1.0 3.4 0.7 0.5 0.5 0.5 2.2 2.6 Total Adjustments 10.5 3.6 (3.1) 4.9 4.4 9.8 3.8 5.3 5.6 5.5 20.2 5.5 5.2 5.7 6.1 22.5 25.8 Adjusted EBITDA 19.0 7.9 16.3 7.7 9.5 41.3 5.5 6.8 7.4 9.5 29.3 7.3 7.5 8.1 8.7 31.6 38.3 Growth Y/Y Revenue 24.5% 31.4% 110.8% 64.2% 45.5% 63.6% 19.4% -36.1% -12.4% 2.4% -10.8% 13.5% 17.9% 17.5% 11.8% 15.1% 19.1% Revenue - Core 24.5% 25.7% 13.9% 22.2% 21.7% 20.7% 11.8% 13.5% 11.8% 10.9% 12.0% 18.6% 22.2% 20.0% 20.0% 20.2% 20.0% Gross Profit 17.2% 19.0% 77.1% 38.5% 34.6% 43.0% 14.1% -32.0% -5.5% 2.5% -8.4% 11.3% 16.1% 18.4% 15.1% 15.3% 20.2% Adjusted EBITDA 15.1% 76.2% 295.7% 58.1% 69.8% 117.2% -30.5% -58.0% -3.9% 1.0% -29.2% 33.0% 9.3% 8.9% -9.0% 7.8% 21.4% Net Income -10.3% 116.7% 1364% -1.7% 112.4% 269.9% -60.3% -91.9% -36.2% -19.4% -71.1% 4.6% 44% 35.1% -36.5% -0.6% 37.7% Margins Gross Profit 69.8% 65.3% 60.5% 58.2% 61.5% 61.0% 62.4% 64.3% 62.8% 61.5% 62.7% 61.2% 63.3% 63.3% 63.3% 62.8% 63.4% Adjusted EBITDA 23.7% 33.1% 38.0% 23.1% 30.3% 31.5% 19.2% 25.0% 25.3% 29.9% 25.0% 22.5% 23.2% 23.5% 24.3% 23.4% 23.9% Net Income (Loss) to Common 10.6% 17.8% 45.3% 8.4% 16.3% 24.0% 5.9% 5.7% 6.1% 12.8% 7.8% 5.5% 7.0% 7.0% 7.3% 6.7% 7.8% Balance Sheet Analysis Total Cash 13.4 8.4 29.7 32.4 31.0 31.0 31.1 31.2 26.9 28.4 28.4 29.2 Total Debt (Lease) 19.5 18.7 15.5 13.2 11.1 3.5 9.6 8.6 7.6 6.5 0.7 5.9 Net Cash / Share ($0.15) ($0.26) $0.35 $0.47 $0.48 $0.67 $0.53 $0.55 $0.47 $0.54 $0.68 $0.58oing great. After next quarters numbers we should see a big move up.